What is Brugada syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Brugada Syndrome

Brugada syndrome is a genetic cardiac condition characterized by distinctive ECG abnormalities (coved ST-segment elevation ≥2mm followed by negative T-wave in right precordial leads) and a high risk of sudden cardiac death in individuals with structurally normal hearts. 1

Definition and Epidemiology

  • Prevalence is approximately 1:2,000 in the general population 2
  • Predominantly affects males in their third to fourth decade of life
  • Male gender is a risk factor for sudden cardiac death 1
  • Can occur in children and neonates, though less commonly 1
  • Primarily inherited in an autosomal dominant pattern 1

Genetic Basis

  • Primary mutation occurs in the SCN5A gene (cardiac sodium channel) 1
  • Non-SCN5A loci have been reported, but specific genes remain unidentified in many cases 1
  • Recent evidence suggests BrS may not be strictly monogenetic, as gene polymorphisms can modify risk 3
  • Most cases are not associated with a single causative gene variant, despite being considered an inherited condition 2

Diagnostic Features

ECG Patterns

  • Type 1 (diagnostic) pattern: coved ST-segment elevation ≥2mm followed by negative T-wave in leads V1-V3 1
  • ECG changes may be dynamic and intermittent, requiring repeated ECGs 1
  • "Corrado index": measures ST elevation at J-point (STJ) and 80ms after (ST80), with Type 1 pattern characterized by STJ/ST80 ratio >1 (downsloping ST segment) 1

Diagnostic Assessment

  • Examine right precordial leads (V1-V3) for characteristic patterns
  • If Type 1 pattern not clear but suspected:
    • Confirm correct lead placement
    • Repeat ECG if necessary
    • Perform high precordial lead ECG (V1 and V2 placed in 2nd or 3rd intercostal space) 1
  • Pharmacological challenge with sodium channel blockers can unmask ST segment elevation in concealed forms 1
  • Fever can unmask or accentuate the Brugada pattern 1

Risk Stratification

High-risk factors:

  • Previous cardiac arrest (increases risk 6-fold) 1
  • Spontaneous Type 1 ECG pattern (higher risk than drug-induced pattern) 1
  • Previous syncope with spontaneous Type 1 ECG pattern 1, 4

Moderate risk factors:

  • Family history of sudden cardiac death 1
  • Male gender 1

Management

High-Risk Patients

  • Implantable cardioverter-defibrillator (ICD) is the only proven effective therapy for preventing sudden death 1
  • Class I indication (strongly recommended) for:
    • Survivors of cardiac arrest
    • Patients with documented ventricular tachycardia
    • Patients with syncope and spontaneous Type 1 ECG pattern 1

Acute Management of Electrical Storm

  • Isoproterenol (boosts calcium channel current) 1
  • Quinidine (inhibits transient outward current) 1

Preventive Measures

  • Aggressive fever management with antipyretics 1, 4
  • Avoidance of drugs that may induce or worsen Brugada ECG pattern 1
  • Regular cardiac follow-up for all diagnosed patients 1
  • Family screening recommended for first-degree relatives 1

Emerging Therapies

  • Quinidine may be effective for long-term management in selected patients 4
  • Epicardial ablation targeting the arrhythmogenic substrate in the right ventricular outflow tract shows promise 2, 3

Important Clinical Considerations

  • ECG findings may be intermittent; repeated ECGs may be necessary 1, 2
  • Fever is a significant trigger for life-threatening arrhythmias (27% of events) 4
  • ICD implantation carries risk of complications (41% major adverse events reported in pediatric patients) 4
  • Asymptomatic patients with spontaneous Type 1 ECG pattern require careful risk assessment 1
  • Electrophysiological testing may be considered for risk stratification in asymptomatic patients with spontaneous ST elevation 1

Special Populations

Pediatric Patients

  • Spontaneous Type 1 ECG pattern and symptoms at diagnosis are predictors of life-threatening arrhythmias 4
  • Management should be age-specific with careful consideration for ICD implantation 4
  • Genetic testing may be particularly valuable in pediatric cases 4

Survivors of Cardiac Arrest

  • May experience neurological sequelae including visual impairment, dystonia, hypersensitivity, and cognitive dysfunction 5
  • Multidisciplinary rehabilitation approach is important for survivors 5

References

Guideline

Brugada Syndrome Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Brugada Syndrome.

JACC. Clinical electrophysiology, 2022

Research

The Diagnosis, Risk Stratification, and Treatment of Brugada Syndrome.

Deutsches Arzteblatt international, 2015

Research

Brugada syndrome and the story of Dave.

Neuropsychological rehabilitation, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.